XML 23 R14.htm IDEA: XBRL DOCUMENT v3.25.1
Net Income Per Common Share
3 Months Ended
Mar. 31, 2025
Earnings Per Share [Abstract]  
Net Income Per Common Share

(4) NET INCOME PER COMMON SHARE

The following sets forth a reconciliation of net income to basic net income attributable to common shareholders to diluted net income attributable to common shareholders (in thousands, except per share amounts):

 

Three Months Ended
March 31,

 

 

2025

 

 

2024

 

Net income, as reported

$

97,052

 

 

$

92,138

 

Participating earnings (a)

 

(299

)

 

 

(600

)

Basic net income attributed to common shareholders

 

96,753

 

 

 

91,538

 

Reallocation of participating earnings (a)

 

2

 

 

 

4

 

Diluted net income attributed to common shareholders

$

96,755

 

 

$

91,542

 

Net income per common share:

 

 

 

 

 

Basic

$

0.40

 

 

$

0.38

 

Diluted

$

0.40

 

 

$

0.38

 

(a)
Restricted Stock Liability Awards (discussed in Note 9) represent participating securities because they participate in non-forfeitable dividends or distributions with common equity owners. Income allocable to participating securities represents the distributed and undistributed earnings attributable to the participating securities. Participating securities, however, do not participate in undistributed net losses.

The following details weighted average common shares outstanding and diluted weighted average common shares outstanding (in thousands):

 

Three Months Ended
March 31,

 

 

2025

 

 

2024

 

Weighted average common shares outstanding – basic

 

240,035

 

 

 

240,505

 

Effect of dilutive securities:

 

 

 

 

 

Director and employee restricted stock and performance-based equity awards

 

1,720

 

 

 

1,901

 

Weighted average common shares outstanding – diluted

 

241,755

 

 

 

242,406

 

 

Weighted average common shares outstanding basic for first quarter 2025 excludes 741,000 shares of restricted stock held in our deferred compensation plan compared to 1.6 million shares in first quarter 2024 (although all awards are issued and outstanding upon grant). For the three months ended March 31, 2025, equity grants of 245,000 shares compared to 127,000 shares in the same period of the prior year were outstanding but not included in the computation of diluted net income because the grant prices were greater than the average market price of the common shares and would be anti-dilutive to the computation.